Trasylol Sales In U.S. And Canada Suspended Temporarily By Bayer In Early November 2007
November 5th, 2007 Posted by: Dr. Cox
Market Withdrawal Or Recall Of Trasylol Seems Possible As Bayer Waits For Final Data From Halted BART Study
(Posted by Tom Lamb at DrugInjuryWatch.com)
In early November 2007 Bayer AG together with the FDA and Men’s health Canada announced that sales of its anti-bleeding drug Trasylol (aprotinin) would be suspended temporarily in the U.S. and Canada while investigations continued about whether Trayslol is linked to a higher risk of death than competing heart surgery drugs.
As we had reported previously, the FDA has been reviewing the safety of Trasylol since early 2006:
In mid-February 2006 the FDA issued a Public Men’s health Advisory informing doctors and patients that the agency was evaluating the safety of Bayer AG’s heart surgery drug Trasylol (aprotinin injection) after new studies had linked it to higher risks of kidney problems, heart attacks, and strokes.